Organic Active Ingredients TRIZ Cases

Adjusting catalyst chloriding effectiveness or reaction temperature maintains desired alkylene oxide production parameters.

Glycogen-based polymers form inclusion complexes with lipophilic compounds to boost aqueous solubility.

Crosslinking edaravone derivatives with alkyl groups forms stable dimers, improving yield and stability while preventing oxidation in aqueous environments.

A transdermal drug delivery system dispenses a drug solution onto the skin and evaporates the solvent through a recovery element.

LSD1 enzymatically removes methyl groups from histone tails to control gene expression levels.

Combining VAL-083 with a Bcl-2 family inhibitor creates a synergistic pharmaceutical composition for glioma therapy.

Combining a cytoskeletal tension regulator with Fas ligand overcomes cancer cell resistance by restoring surface Fas receptors for targeted apoptosis.

Oral CpG-ODNs activate TLR9 to inhibit TLR4-mediated inflammation, improving survival rates in necrotizing enterocolitis.

Segmented particles with internal adhesion promoters prevent dose dumping when crushed or exposed to alcohol.

Targeting the NS5A protein, these compounds overcome inadequate viral replication inhibition found in current treatments.

A pharmaceutical composition uses medium chain oil to solubilize estradiol and suspend progesterone for consistent delivery.

Substituted imidazo[4,5-b]pyridine compounds inhibit B-Raf kinase activity to resolve specificity and efficacy limitations against common cancer mutations.

Alicyclic benzopyrone derivatives target dopamine D2/D3 and serotonin 5-HT1A/2A receptors, reducing extrapyramidal side effects while treating schizophrenia.

Modified fatty acids activate AMPK to reduce hepatic glucose production, addressing hypoglycemia risks from existing diabetes treatments.

Targeting glutaminolysis via GLS1 inhibition addresses metabolic dysregulation in pulmonary hypertension, reducing vascular remodeling.

Adding a Rho kinase inhibitor to the culture medium improves corneal endothelial cell adhesion and density, reducing cell death from limited donor supply.

Desogestrel inhibits proliferation in ER-negative Ah receptor-positive breast cancer cells through targeted molecular network analysis.

Amphiphilic peptides protect siRNA from nuclease degradation and rapid clearance, enabling efficient gene silencing in physiological conditions.

Specific molecular structures enhance AKT1 inhibition effectiveness while resolving isoform specificity limitations.

Anti-inflammatory small molecule coatings on neurological implants reduce foreign body responses and improve device longevity.

Optimized chemical structures of TLR7 agonists enhance pathogen defense while minimizing autoimmune response risks.

Pyridine-sulfonamide compounds target MAPK pathways to reduce interleukin 1 beta levels, addressing inadequate treatments for NASH and IPF.

Substituted nitrogenous heterocycle compounds target the ADP/ATP translocator ANT to induce apoptosis in cancer cells.

Triciribine formulations extend shelf life by reducing hemolysis and preserving functional integrity.

Radiolabeled somatostatin receptor binding compounds paired with PARP inhibitors target neuroendocrine tumors through synergistic mechanisms.

Modified RNAi agents inhibit APOC3 expression, resolving stability and efficacy trade-offs in hypertriglyceridemia treatment.

Combination therapy with DFMO and transport inhibitors depletes intracellular polyamine pools, inhibiting metastatic colon cancer growth.

SNAC carrier enables rapid oral absorption of methylcobalamin, resolving high inter-subject variability in traditional treatments.

Phenyl-triazolo-pyridine compounds selectively activate GPR-40 receptors, providing novel treatment options for type II diabetes beyond sulfonylureas.

Imidazooxazole derivatives inhibit B-RAF V600E kinase to suppress tumor growth where conventional therapies lack effective targets.

Thermal cycling creates stable L-HA and H-HA hybrid complexes, resolving viscosity instability in high molecular weight solutions.

ACI-3024 dosing overcomes toxicity and specificity limits of kinase inhibitors by maintaining therapeutic cerebrospinal fluid levels.

Citric acid buffers aqueous carmoterol to prevent oxidation, ensuring chemical stability at low concentrations.

Biodegradable naltrexone implant eliminates daily oral compliance while reducing side effects through sustained release.

Combining EZH2 and SCD1 inhibitors enhances anti-tumor efficacy in solid tumors.

Cyclodextrins encapsulate meloxicam to form inclusion complexes that enhance aqueous solubility, resolving poor bioavailability and delayed pain relief.

Combining iadademstat with PD(L)1 inhibitors modifies tumor epigenetics to enhance antitumor response.

Attenuates chemokine-mediated fugetactic effects that repel immune cells, enabling combination therapies to effectively target and eradicate tumors.

Group II metabotropic glutamate receptor modulators increase rebound burst firing and sleep spindle density.

Deuterated and methylated N4-hydroxycytidine analogs reduce cellular mutagenicity by slowing metabolic conversion into harmful deoxyribonucleotides.

Specific substituent groups on the purine scaffold enhance inhibitor potency and selectivity for Mer kinase over other kinases.

Chitosan powder absorbs bodily fluids to form a hemostatic barrier, resolving gastrointestinal bleeding control failures.

Measuring let-7, HMGA2, and LIN28 markers identifies patients benefiting from DFMO therapy while reducing ototoxicity risks.

A bispecific antibody binds CAPRIN-1 proteins on cancer cells to enable targeted delivery of antitumor agents.